Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Cellink in a directed new issue of shares of MSEK 100
Mandate

Vinge has advised Cellink in a directed new issue of shares of MSEK 100

June 05, 2018 Capital Markets and Public M&A

Vinge has advised Cellink AB (publ) in connection with a directed new issue of shares to Swedish and internationally well-reputed investors such as the Swedish Fourth AP Fund (AP4), Carl Bennet AB, Claes Dinkelspiel and Handelsbanken Fonder.

The subscription price in the amount of SEK 132.50 has been determined through a so called accelerate bookbuilding procedure. As a result of the new issue, Cellink will receive approximately MSEK 100. The proceeds generated by the new issue of shares will be used, among other things, in order to perform acquisitions in accordance with Cellink’s growth strategy, continued global expansion and future development of its product portfolio. Carnegie Investment

Bank has acted as financial advisor and sole bookrunner.

Vinge’s team consisted of partner Anders Strid together with, among others, Wibeke Sorling and company assistant Camilla Andersson.

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025